The Heart of Healthcare | A Digital Health Podcast đź“Ł Digital Health Download: December 2025
8 snips
Dec 1, 2025 Explore the rise of Eli Lilly as the first trillion-dollar healthcare company and the impacts of GLP-1 drug dynamics. Delve into two significant longevity funding rounds, with $298M and $60M raises that highlight celebrity influence in health startups. Discover the ramifications of CVS’s $5.7B write-down and the educational landscape shift as nursing loses its 'professional' status. Finally, unravel a telehealth scandal with federal convictions, sparking questions about ethics in healthcare.
AI Snips
Chapters
Transcript
Episode notes
Two Faces Of The Longevity Boom
- Longevity funding is polarizing with mega Series Bs and all-angel rounds coexisting.
- Famous founders and influencer channels are driving outsized valuations and distribution strategies.
GLP-1s Fueled A Trillion-Dollar Pharma
- Eli Lilly reached a trillion-dollar valuation driven by GLP-1 sales and terzepatide efficacy.
- Price cuts and broader access strategies mean Lilly will likely chase volume to sustain growth.
Why Big Health M&As Often Collapse
- Large acquisitions often fail because buyers overestimate synergies and mismanage integration.
- Talent loss, cultural mismatch, and unrealistic ROI assumptions kill many deals.